Jan Pinkas
Technik-/Wissenschafts-/F&E-Leiter bei PYXIS ONCOLOGY, INC.
Aktive Positionen von Jan Pinkas
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PYXIS ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.04.2022 | - |
| Corporate Officer/Principal | 01.08.2021 | 12.04.2022 |
Karriereverlauf von Jan Pinkas
Ehemalige bekannte Positionen von Jan Pinkas
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - | - |
Ausbildung von Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Jan Pinkas
- Erfahrung